Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Stony Brook UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)(MEANING-20) | withdrawn | — | 0 | TakedaINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 1 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 0 | Oct 17, 2023 | clinicaltrials |
| NCT05032079 | Subzero and Scorpion Trial | withdrawn | N/A | 0 | Larkin Community HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05466916 | EDITS Pilot Study for Gynecologic Cancer Survivors | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05821582 | Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens | withdrawn | — | 0 | Sanguine BiosciencesINDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05961696 | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04265274 | Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. | withdrawn | Phase 2 | 0 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03875053 | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer | withdrawn | N/A | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS(BISECT) | withdrawn | Phase 1 | 0 | Racura Oncology LtdINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01632436 | Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment(Hepatic) | withdrawn | Phase 1 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04176900 | 3D Printed Rigid Bolus Versus Silicone Bolus for Treatment of Tumors Involving the Skin: A Comparative Study | withdrawn | N/A | 0 | Nova Scotia Cancer CentreOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT05431439 | Omics of Cancer: OncoGenomics | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03406273 | Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma | withdrawn | N/A | 0 | Giselle ShollerOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05092750 | Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 28, 2023 | clinicaltrials |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04917224 | Study of LUNG Stereotactic Adaptive Ablative Radiotherapy(LUNG STAAR) | withdrawn | N/A | 0 | Baptist Health South FloridaOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03803761 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2023 | clinicaltrials |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | withdrawn | Phase 2 | 0 | Armando GiulianoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05567679 | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | withdrawn | Early Phase 1 | 0 | Edwin Posadas, MDOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02535988 | Abscopal Effect for Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT03991104 | SOX-based CRT for Esophageal Cancer. | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT04170335 | Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients | withdrawn | — | 0 | The Cleveland ClinicOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Incyte Biosciences International SàrlINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05299580 | "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" | withdrawn | Phase 2 | 0 | Fondazione Melanoma OnlusOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT05045404 | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03623984 | Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05201001 | APX005M in Patients With Recurrent Ovarian Cancer(APX005M) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05412706 | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy(Bohème) | withdrawn | Phase 2 | 0 | Ospedale Policlinico San MartinoOTHER | 0 | Sep 8, 2023 | clinicaltrials |
| NCT04952584 | Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers | withdrawn | Phase 1 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | withdrawn | Phase 2 | 0 | Bradley A. McGregor, MDOTHER | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05287971 | Standard of Care Lifestyle Support for Stage III NSCLC Patients(PERCUSSION) | withdrawn | — | 0 | Maastricht Radiation OncologyOTHER | 0 | Sep 6, 2023 | clinicaltrials |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | — | 0 | Inova Health Care ServicesOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05054400 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05230888 | Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer Patients | withdrawn | — | 0 | University of HullOTHER | 1 | Sep 1, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Oct 19, 2023source: clinicaltrials